Low-dose subcutaneous ketamine infusion and morphine tolerance
- 1 October 1999
- journal article
- case report
- Published by Wolters Kluwer Health in Pain
- Vol. 83 (1) , 101-103
- https://doi.org/10.1016/s0304-3959(99)00096-2
Abstract
The NMDA receptor has been reported to be involved in opioid tolerance. Adjuvant subcutaneous infusion treatment with (very) low-dose ketamine, a NMDA receptor antagonist, improves analgesia and at the same time appears to reduce morphine tolerance. Three cases are presented.Keywords
This publication has 7 references indexed in Scilit:
- Decrease of tolerance to, and physical dependence on morphine by glutamate receptor antagonistsEuropean Journal of Pharmacology, 1997
- The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and DiscontinuationPharmacology, 1997
- Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in ratsPain, 1996
- The Effects of NMDA Receptor Antagonists and Nitric Oxide Synthase Inhibitors on Opioid Tolerance and Withdrawal Medication Development Issues for Opiate AddictionNeuropsychopharmacology, 1995
- Perspectives on the N-Methyl-?-Aspartate/Nitric Oxide Cascade and Opioid ToleranceNeuropsychopharmacology, 1995
- Mechanisms of hyperalgesian and morphine tolerance: a current view of their possible interactionsPain, 1995
- Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patientJournal of Pain and Symptom Management, 1995